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Background: The efficacy of wearing compression stockings on clinical vessel disappearance following sclerotherapy of
telangiectasias and reticular veins has been a matter of debate for half a century.
Objective:To determine the relative efficacy of compression following sclerotherapy and to determine its impact on general
quality of life in a prospective randomized open-label trial.
Methods: Female patients seeking treatment of telangiectasias and reticular veins and presenting comparable areas of
telangiectasias on the lateral aspect of the thigh (C1A or SEPAS1PN) were randomized to wear medical compression
stockings (23 to 32 mm Hg) daily for 3 weeks or no such treatment following a single session of standardized liquid
sclerotherapy. Outcome was assessed by patient satisfaction analysis and quantitative evaluation of photographs taken
from the lateral aspect of the thigh before and again at 52 days on the average after sclerotherapy by two blinded expert
reviewers. Patients completed a quality of life questionnaire (SF-36) before treatment and again at the control.
Results:Data of 96 of 100 randomized patients could be evaluated. Patient satisfaction with the outcome of treatment was
similar in the two groups. Objective assessment of clinical vessel disappearance revealed a benefit of wearing stockings (P
 .026) corresponding to a NNT (number needed to treat) of 4.7 patients to get a vessel disappearance score higher than
6. The interobserver agreement was very high (intraclass correlation coefficient 0.93). Compression was well tolerated
with a low rate of discomfort claims (mean 17.5%). Micro-thrombi were rarely observed in either group, but still less
prevalent in the compression group. The rate of pigmentation and matting was low and did not differ significantly
between the two groups. Physical and mental quality of life scores in women seeking treatment of telangiectasias were
similar to those of a healthy control population. Treatment had no impact on general quality of life.
Conclusion: Wearing compression stockings (23 to 32 mm Hg) for 3 weeks enhance the efficacy of sclerotherapy of leg
telangiectasias by improving clinical vessel disappearance. (J Vasc Surg 2007;45:1212-16.)The use of compression following sclerotherapy for
telangiectasias and reticular veins varies much between
different countries.1 In France, Canada, and Italy, only a
minority of phlebologists apply compression after sclero-
therapy for telangiectasias, while it is routinely used in
Switzerland and Germany.1,2 The duration of compression
varies between 24 hours and more than 3 weeks. The
compression modality includes medical compression stock-
ing (20 to 40 mm Hg)2-8 and various forms of compression
bandages.2,3,5 Some phlebologists use local exocentric
compressive pads in addition.3,4 In recent trials, postscle-
rotherapy compression varied from no compression9 to 72
hours compression for telangiectasias4,8 and 1 week for
reticular veins.5,6,8
Effectiveness was shown for telangiectasias greater than
0.5 mm diameter4 and the best effect observed in patients
wearing compression stocking (20 to 30 mm Hg) for 3
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1212weeks.7 A certain benefit of compression was already ob-
served after 3 days and 1 week.
Compression is thought to enhance the efficacy of
sclerotherapy by reducing the formation of postsclero-
therapy thrombi, as well as pigmentation and matting by
minimizing inflammation and angiogenesis.10 However,
medical compression stockings (20 to 30 mm Hg) do not
allow compression of the lower limb veins in the standing
position.11 For telangiectasias, 80 mm Hg compression
pressure is required to produce a complete emptying of
blood as the patient is standing.10 At the thigh, compres-
sion stockings exert only 41% to 74%10 from the compres-
sion of the ankle, therefore, 23 to 32 mm Hg compression
stockings, apply approximately only 10 to 18mmHg at the
thigh. For this reason, efficacy of applying compression
stockings after sclerotherapy of telangiectasias of the thigh
is debatable.
The great diversity of methods reflects personal experi-
ence and a lack of evidence to propose postsclerotherapy
compression.
Patients are often reluctant to use compression there-
fore, it is mandatory to assess its efficacy to convince the
patients to wear his compression stockings after sclerother-
apy.
This study was designed to evaluate if wearing com-
pression stockings after sclerotherapy of telangiectasias as
well as their feeding reticular veins can enhance clinical
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of life. The study was not intended to analyze the role of the
vessel size in outcome since such data have been provided
before.
METHODS
Patients. One hundred consecutive, female patients
with primary telangiectasias and reticular veins on the lat-
eral aspect of the thigh (C1A or SEPAS1PN) were included in
the study between September, 2003 and September, 2005
in a private office of vascular medicine. The study was
approved by the ethics committee of the CentreHospitalier
Universitaire Vaudois, Lausanne, Switzerland. Patients
signed consent after full information. All patients under-
went a clinical examination and color-flow duplex imaging
(CFDI) of their veins. They were devoid of reflux lasting
more than 1 second in the deep veins, saphenous trunk,
saphenous junction, saphenous tributaries, or perforating
veins. All had fully compressible deep and superficial veins.
Further exclusion criteria were previous sclerotherapy and
allergy to chrome. By design, we only considered patients
with aesthetic problems and normal duplex who sought
treatment for the first time. As no patient declined partici-
pation, and no patient reported allergy to chrome, no
patient was excluded from the study.
Main outcome of the study was the clinical vessel
disappearance rate (Table I).
The sample size required for this trial was calculated on
the basis on our previous sclerotherapy study, which com-
pared different sclerosing agents,5 as it was not possible to
perform a power calculation on the previous compression
study either because of the lack of statistics or a different
statistical methodology. In our previous sclerotherapy
study,5 a statistical significant difference between sclerosing
agents could be demonstrated, therefore, it was possible to
perform a power calculation for this study since the meth-
odology is similar. Precalculation of the sample required
size showed that to detect a true difference of half a
standard deviation at a one sided 5% significance level with
a power of 80%, exactly 100 patients are required, 50 in
each group. Median age of participants was 47 years (range
20 to 72).
Procedure. The study was designed as a prospective
Table I. Outcome parameters: assessment method and sta
Outcome
Main outcome Clinical vessel disappearance Objec
pho
Patien
scale
Secondary
outcomes
Side effects Identi
was
pho
Tolerability of wearing stockings Visual
Effect of wearing stockings on general
quality of life
Qualit
ANOVA, analysis of variancerandomized open-label trial. To have comparable skin areatreated, without any influence of a potential saphenous
reflux, only telangiectasias located on the lateral aspect of
the thigh were considered for the study. The patients had
comparable types and sizes of telangiectasias and reticular
veins: the diameter of reticular veins ranged between 1 to
2.9 mm, that of telangiectasias between 0.2 and 1 mm.
These vessels could be identified from a distance of 2meters
by the human eye and the camera.
One lower limb per patient was treated in a single
session. If both thighs were affected, only the left one was
treated and evaluated for the study as defined by the pro-
tocol.
Prior to treatment, each patient was randomly assigned
(computer generated random table) either to no compres-
sion or to compression for 3 weeks following sclerotherapy.
The whole treated thigh area was photographed immedi-
ately before sclerotherapy in supine position in order to
avoid arbitrary selection of a limited skin surface. The same
digital camera (Coolpix 990, Nikon, Tokyo, Japan), light-
ing conditions (flash), and focal distance were used. Chro-
mated glycerin (Scleremo, Laboratoires Bailleul, Paris,
France) was used in all patients as the sclerosing agent as
previously described.5
Injections were performed with a 2 ml silicone syringe
and a 30 G ½-inch needle with the patient in supine
position. Sixty to 100 injections were made on the lower
limb during the session. The maximum amount of scleros-
ing solution injected was 10 ml per patient. Reticular
feeding veins were injected prior to injection of the telan-
giectasias. Patients remained supine for 5 minutes after the
last injection. In the compression group, a thigh-length
stocking Sigvaris 702 Top Fine (23 to 32 mm Hg) was
applied respecting the individual lower limb dimensions.
Patients were asked to wear the compression stockings daily
for 3 weeks and to remove it during night time. Patients
filled in a quality of life questionnaire (SF-3612) prior to
treatment.
Assessment. Patients were scheduled 6 weeks after
treatment. They were questioned about their satisfaction
using a visual analogue scale ranging from bad perception
(0) to great satisfaction (100). Patients in the compression
group were questioned about any discomfort produced by
wearing compression hosiery (0 excellent tolerability to
s used, respective to each outcome
Assessment method Statistics
ssessment through blinded analysis of
phs by two experts
Student t-test
faction reported on an analogue visual Student t-test
n of side effects by the treating physician
hed with side effects reported from the
phic analysis by blinded experts
2 tests
gue scale Mean, median, STD
ife questionnaire SF-36 ANOVA modeltistic
tive a
togra
t satis
ficatio
matc
togra
analo
y of l100 high discomfort), and compliance. Compliance with
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means. The SF-36 questionnaire was again completed.
A control photograph was taken under the conditions
set for the pretreatment assessment. Two independent
blinded experts analyzed the photographs using a visual “a
priori” score of vessel disappearance. A score of 0 meant no
improvement, whereas a score of 10 indicated complete
vessel disappearance (Fig 1). The experts also evaluated
possible side effects using a similar score. Both reviewers
were experts in phlebology, with extensive experience with
sclerotherapy. The assessment method had been validated
in a previous study5 performed in collaboration with the
same experts, where it showed to have a high inter-observer
agreement as well as a good reproducibility. The experts
analyzed the global area of the photograph and not only a
section of it. This method avoids selecting arbitrarily a small
area and has the advantage that treatment result is not
influenced by external factors such as feeding veins and new
variables like the choice of a very limited area. After calcu-
lating the interobserver reliability, the mean score of the
ratings of the two experts was used for further analysis.
The treating physician, not blinded to the treatment,
checked for side effects reported by the patients. He also
identified micro-thrombi, pigmentations, or matting, as
they may be difficult to evaluate on the photographs.
Statistics. Power calculation was performed using the
Java Application of Lenth R.V. 2006. Student t test with a
level of significance of P  .05 was used to analyze patient
age, the time interval to the control picture, satisfaction
graded by the patient, and the efficacy score determined by
Fig 1. Example of a patient pretreatment (A) and 46 days after
(B) control photographs with the respective experts blinded vessel
disappearance score. Evaluation: vessel disappearance score expert
one: 8, expert two: 9.the experts. With the hypothesis that compression ought tobe better than no compression, outcome related statistical
tests were performed one tailed. The interobserver agree-
ment on the photographs was analyzed by intraclass corre-
lation coefficient. In order to compare different outcome
groups, the patients were divided into tertiles related to the
vessel disappearance score. To calculate commonly used
measures of therapeutic effect (absolute and relative risk
reduction (ARR, RRR), number needed to treat (NNT)
the lowest third of the vessel disappearance score (score 1 to
6) was defined as unfavorable. Potential differences of side
effects were analyzed by 2 tests. The influence of the
treatment on SF-36 was calculated with an analysis of
variance (ANOVA) model. Pearson correlation coefficients
were calculated between the different variables.
RESULTS
Evaluation of the photographic images. Analysis of
the photographs using the vessel disappearance score re-
vealed a very good agreement between the two indepen-
dently working blinded reviewers (intraclass correlation
coefficient  0.93).
Efficacy. One hundred patients were randomized, 49
in the group without compression (WCG) and 51 in the
group with compression (CG). Three patients of the WCG
and one patient in the CG did not return for control.
Therefore, 96 patients were included for the final efficacy
analysis: 46 in the WCG and 50 in the CG.
There were no differences between the two groups for
age and the time that elapsed until the postsclerotherapy
photograph was taken. Time interval to control was 53.5
(/- 22) days in the no compression group and 50.6 (/-
17) days in the compression group. Four patients were
controlled before 35 days (minimum 30 days), and four
other patients missed their appointment and came back to
the control more than 100 days (maximum 151 days) after
the intervention. A statistical analysis excluding the patients
controlled before 5 weeks and after 7 weeks (23 excluded in
the WCG, and 13 in the CG), showed no difference in the
results. Indeed, the significant difference of the mean ex-
pert score was higher in favor of compression treatment,
and furthermore, it did not change the results of the quality
of life analysis. Therefore, we decided not to exclude these
patients from the final analysis.
Patient satisfaction was the same in either group: 75.3
(/- 20.6) for the WCG and 77.3 (/- 18.1) for the CG
(not significant, ns).
Objective assessment of the result by the experts re-
vealed a significant benefit of compression therapy. The
mean score was 6.28 (/-2.1) for theWCG and 7.05 (/-
1.7) for the CG (P .026). Although patient satisfaction
revealed no significant difference between the two treat-
ment modalities, there was a significant positive correlation
with the mean expert score (r  .21, P  .05). Vessel
disappearance score analysis (Fig 2) showed that 43% of the
patients wearing no compression and only 24% of the
patients wearing compression had a less favorable outcome
(vessel disappearance score 1 to 6). On the other hand, 76%
of patients wearing compression had a satisfying outcome
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patients without compression reached this score value. This
corresponds to an ARR of 21.5% and a RRR of 27.6%
resulting into a NNT of 4.7. In other words, about five
patients have to be treated with compression for one to
obtain a vessel disappearance score higher than 6.
Patients rarely reported discomfort provoked by com-
pression stockings, the median score being 10, the mean
score 17.5 (/-21.3) on a visual analogue scale of 0 to
100. As many as 38% of the patients experienced no dis-
comfort (score 0). Only two patients had a discomfort score
of more than 50.
The rate of complications was positively correlated with
the discomfort of wearing stockings (r 0.29, P.05). In
other words, patients who claimed a high discomfort of
wearing stockings presented more complications.
Although micro-thrombi, matting, and pigmentations
could sometimes be difficult to see on photographs, there
was no discordance between the number of side effects
reported from the physician and the ones reported from the
blinded experts. Micro-thrombi were rarely observed in
either group (15.2% in the no compression group, 10% in
the compression group), but still less prevalent in the
compression group (Table II). The rate of pigmentation
and matting was low and did not differ significantly be-
Fig 2. Vessel disappearance score: patients are divided into ter-
tiles related to the vessel disappearance score. This analysis of three
different vessel disappearance score demonstrates that all patients
benefit from compression, enhances efficacy of sclerotherapy, and,
also, avoids failures.tween the two groups.No serious side effects were encountered.
Quality of life. Ninety-three SF-36 questionnaires
could be evaluated (45 WCG, 48 CG). The mean physical
score was 54.1 prior to treatment and 54.4 at the control
(52 days on the average) (ns). The mental score was 47.8
before treatment and 48.5 thereafter (ns). The physical
score showed a statistical trend in favor of compression.
The mean physical score is slightly over and the mean
mental score slightly under the general populations norm
(mean  50 /-10).
DISCUSSION
Although the utility of compression after sclerotherapy
of telangiectasias is recommended in several countries, pro-
spective studies demonstrating its efficacy are scarce, and
include rather small numbers of patients. This prospective,
randomized controlled study brings evidence that postscle-
rotherapy compression enhances vessel clearing after one
single session of sclerotherapy of telangiectasias and their
feeding reticular veins. We designed the study to evaluate
the effect of compression stocking at the thigh, instead of at
the calf were the pressure applied is higher. As the practi-
tioner is often confronted with patient presenting telangi-
ectasias at the thigh, the results of this study should help
him in his treatment strategy. If compression enhances
vessel disappearance at the thigh, it is probably also the case
for the calf but the contrary could be not true.
As the compression pressure with 23 to 32 mm Hg
compression stockings is low at the thigh and is much lower
than the compression needed to empty telangiectasias from
their blood,10 it raises the question of mechanism of action.
Hypothesis of action could be that compression does not
act by reducing the lumen of the telangiectasias, but has an
anti-inflammatory action in the peri-venous space. Com-
pression stockings are classified according to the pressure
exert at the ankle at rest. Their behavior when the patient is
exercising may be different, including variation of pressure
and the massage effect. Compression stockings could also
reduce the blood flow from the feeding reticular veins and,
therefore, enhance clinical disappearance of telangiectasias.
The absolute benefit of wearing stockings seems rela-
tively small. However, departing from the patients’ expec-
tation that telangiectasias would clear totally or almost
totally, an increase of vessel disappearance from 63% to 70%
appears to be important. Furthermore, the number needed
Table II. Comparison of the side effects
No compression Compression
Micro-thrombi 7 (15.2%) 5 (10%)
Thrombus in reticular vein 0 1
Pigmentation 4 4
Matting 1 2
Micro-thrombi were rarely observed in either group, but still less prevalent
in the compression group. The rate of pigmentation and matting was low
and did not differ significantly between the two groups.to treat is low: only five patients have to use compression for
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ance score under 6.5) was significantly more frequent in the
no compression group (43% vs 24%). This means that
compression not only enhances efficacy of sclerotherapy
but also avoids failures.
Patient satisfaction showed a trend in favor of compres-
sion. In keeping, a significant correlation between the
patient satisfaction score and the mean expert score was
observed. As one can expect, it is difficult to compare such
data because of the different nature of evaluation tools.
Despite the fact that the patients rely in part on their visual
memory and personal appreciation of the problem, and that
the experts rely on objective images for the assessment of
the results, a similar trend was noticed.
Side effects were scarce in both groups with a trend
toward less micro-thrombi in the compression group (10%
vs 15.2% in the WCG). The low incidence of side effects
may be attributed to the sclerosing agent (chromated glyc-
erin), which has been shown in our earlier study comparing
different agents, to have a low complication rate.5 In other
studies assessing compression, polidocanol 0.25% to 0.75%,
a mixture of dextrose and sodium chloride (Sclerodex),
chromated glycerin (Scleremo) and sodium tetradecyl sul-
fate 0.15% to 0.25%were used, which showed higher rate of
pigmentation in the no compression group (40%4 and
100%,7 respectively). In these studies, compression re-
duced the rate of pigmentation to 28.5%4 and to 20%,7
respectively.
There is a significant correlation between discomfort of
wearing stockings and the rate of complication in our trial,
which could suggest that these patients did not wear their
stockings.
Quality of life assessment shows that patients seeking a
treatment for telangiectasias have a normal physical and
mental score. Therefore, in aesthetic telangiectasias cannot
be considered as a disorder interfering with general quality
of life. One session of treatment neither modified the
mental nor the physical score. The degree of discomfort
with wearing stockings was low and did not have a measur-
able negative impact.
CONCLUSION
In conclusion, 3 weeks of compression after sclerother-
apy of telangiectasias and reticular veins improves the ob-
jectively assessed appearance after 52 days on the average,
but does not influence the quality of life of the patients.
There were too few adverse events for the effects of com-
pression to analyze its impact in this study population.The authors thank Werner Blättler (Zürich) for critical
reading of the manuscript and Felix Amsler (Biel-Benken)
for the statistical analysis of the data.
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